Patent: 10,086,046

Summary for Patent: 10,086,046

Title:	Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory T cells
Abstract:	The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (T.sub.Reg) in an organism and various methods in which the agents according to the invention are used.
Inventor(s):	Paulsen; Daniela (Wuppertal, DE), Brunner; Nina (Essen, DE), Bray; Dorothy (Buckinghamshire, GB)
Assignee:	AiCuris GmbH & Co. KG (Wuppertal, DE)
Application Number:	15/439,845
Patent Claims:	see list of patent claims

Patent Landscape Analysis: US 10,086,046 (hIL-2 mutein expanded Treg therapy for autoimmune disease)

US 10,086,046 claims an ex vivo cell-processing and adoptive transfer regimen that uses PBMCs expanded into a regulatory T cell (Treg) enriched population by contact with a human interleukin-2 (hIL-2) mutein containing specific amino-acid substitutions at positions 20, 88, and/or 126 (per SEQ ID NO:1). The method is directed at autoimmune diseases including type I diabetes, multiple sclerosis, and systemic lupus erythematosus (SLE). The claim set also provides narrower composition/variant coverage for specific substitutions (e.g., N88R, N88G, N88I; D20H, D20I, D20Y; Q126L) and adds optional combination with standard immunosuppressants.

What do the claims actually require, element by element?

Independent claim 1: ex vivo contact, Treg induction, and adoptive transfer

Claim 1 is a “process of treatment” with three core technical steps:

1. Source material

• “Peripheral mononuclear blood cells (PBMCs) derived from a first organism”

2. Key biological driver (hIL-2 mutein with position constraint)

• “contacting” PBMCs with a “mutein of human interleukin-2 (hIL-2 mutein)”
• the mutein must have “an amino acid substitution in at least one of the positions 20, 88, or 126” numbered against the hIL-2 wild-type sequence in SEQ ID NO: 1
• the contact must be to “obtain a cell population which comprises regulatory T cells”

3. Delivery and indication

• “introducing the cell population into a second organism”
• treating “autoimmune disease” limited to: type I diabetes, multiple sclerosis, and SLE

Dependent claims tighten the IL-2 mutein definition

• Claim 2: first and second organisms are the same or same species (self-administration and homologous transfer framing).
• Claim 3: specifies position 88: N88R, N88G, or N88I.
• Claim 4: allows “at least one further amino acid substitution” in any other position, but requires it be conservative.
• Claim 5: specifies position 20: D20H, D20I, or D20Y.
  Note the claim text includes a likely typographical anomaly (“D200”) that, if uncorrected in prosecution/interpretation, can affect scope.
• Claim 6: specifies position 126: Q126L.
• Claim 7: optional regimen adds “administering … an immunosuppressant.”
• Claim 8: lists a broad immunosuppressant menu, covering corticosteroids, classic immunosuppressants, calcineurin inhibitors, antiproliferatives, mTOR inhibitors, kinase inhibitors, anti-T cell therapies, anti-CD25, and multiple biologics (including anti-TNF agents).

Scope consequence: claim 1 is broad on “at least one position,” narrow on “Treg outcome”

Claim 1 does not require a particular single substitution identity at 20, 88, or 126 beyond “an amino acid substitution.” It does require the functional outcome: the cell population “comprises regulatory T cells.” This creates two major claim-construction pressure points:

• Variant breadth: Any substitution at 20 or 88 or 126 could fall within claim 1, but claims 3/5/6 narrow the conventional “commercially legible” sub-variants.
• Outcome boundary: “comprises regulatory T cells” is less exact than “CD4+CD25+FOXP3+” type gating, but it still anchors infringement to a Treg-containing product.

What is new or defensible about the claimed IL-2 mutein approach?

Position-based IL-2 muteins for biased Treg biology

The claim architecture tracks a known strategy in IL-2 therapeutics: modifying IL-2 to preferentially expand or support Tregs over effector T cells through receptor signaling bias. The patent’s novelty is anchored to:

• using IL-2 mutein(s) with substitutions at positions 20, 88, and/or 126 (per SEQ ID NO:1 numbering)
• applying that mutein ex vivo to PBMCs to generate a Treg-enriched cell population
• then performing adoptive transfer to treat autoimmune diseases

Critical observation on defensibility

The defensibility is less about “adoptive Treg therapy” per se and more about the combination of:

• ex vivo PBMC contact with specific IL-2 mutein variants, and
• treatment of specified autoimmune indications via reinfusion of the resulting cell population.

If the underlying prior art already discloses ex vivo Treg generation using IL-2 variants, then infringement reduces to whether the prior art includes substitutions at the claimed positions with the same numbering scheme and functional Treg readout.

Where does the claim landscape face prior-art pressure?

1) Ex vivo Treg induction using IL-2 has extensive disclosure history

Adoptive Treg therapy has long used IL-2, including ex vivo stimulation and expansion workflows in autoimmune settings. The landscape pressure concentrates on whether prior documents used:

• human IL-2 muteins rather than wild-type IL-2, and
• IL-2 mutein substitutions at 20/88/126 with the same sequence numbering, and
• whether the documents target the same autoimmune indications.

2) IL-2 muteins with receptor-biased variants are known, but “position identity” is the gating issue

Many IL-2 engineering programs target select residues to bias receptor engagement (e.g., reduced CD122/effector signaling or enhanced CD25/Treg bias). For infringement under claim 1, the mutein must have substitutions at at least one of the three claimed positions. That means:

• If prior art discloses a mutein with substitutions at unrelated positions, it may avoid claim 1.
• If prior art discloses substitutions at the same positions but in a different sequence numbering scheme, litigation depends on the mapping to SEQ ID NO:1.

3) The optional immunosuppressant add-on (claims 7-8) is unlikely to be novelty

Claim 7 and 8 broadly list standard immunosuppressants used in autoimmune therapy. Even if those combinations are used in the specification, claim validity often relies on the IL-2 mutein/Treg process, not on the background immunosuppressant list. If the ex vivo Treg method is weak against prior art, adding a known immunosuppressant generally does not restore novelty unless a specific synergy or procedural requirement is claimed.

Claim-by-claim vulnerability and strength assessment

Claim 1 (independent): medium strength on “method steps,” medium-to-high vulnerability on “mutein position breadth”

• Strength: explicit process: PBMC contact → Treg-containing cell population → infusion → specified autoimmune diseases.
• Vulnerability:
  • “substitution in at least one of positions 20/88/126” can overlap many IL-2 engineering variants if those residue positions are common engineering hotspots.
  • “regulatory T cells” could be met by diverse gating strategies; if prior art reports “Treg-like” or FOXP3+ populations, claim 1 can be hard to avoid.

Claim 3 (N88 variants): narrower, but likely to collide with any “N88x” IL-2 engineering prior work

• Covers N88R, N88G, N88I.
• If any earlier filings disclose N88R/G/I in IL-2 and use it for Treg expansion or therapy, claim 3 becomes a focal collision point.

Claim 5 (D20 variants): narrower and residue-specific

• Covers D20H, D20I, D20Y.
• If D20 substitutions appear in known IL-2 mutein batteries, this claim is a direct overlap risk.
• The “D200” text anomaly requires close reading in legal interpretation, but it does not broaden the claim as written; it may narrow or create interpretive issues rather than expanding.

Claim 6 (Q126L): residue-specific, possibly narrower

• Q126L is a single variant.
• If prior art includes Q126L in any context for immune bias or Treg therapy, the collision is binary: either the prior art anticipates or it does not.

Claim 4 (further conservative substitutions): creates a “halo” around the defined variants

• Once a substitution exists at 20/88/126, additional conservative changes anywhere else can keep the mutein inside claim 4.
• This is a standard claim-extension strategy that can increase infringement surface against “nearby” engineering variants that change stability or manufacturing while preserving functional class.

Claims 2, 7, 8: process logistics plus known concomitants

• Claim 2 is procedural.
• Claim 7-8 are broadly enumerative and typically not a differentiator unless the method requires a specific timing or procedural dependency not captured by claim language.

How to read this patent for enforcement and design-around

What products or workflows are most likely to infringe

The highest-probability infringement profile is:

• a therapeutic workflow that uses PBMCs ex vivo
• contacted with an hIL-2 mutein bearing at least one substitution at position 20, 88, or 126 (SEQ ID NO:1 numbering)
• produces a Treg-containing product
• reinfuses into a patient to treat type I diabetes, MS, or SLE

Practical design-around levers

The claim set points to three main avoidance routes:

1. Residue avoidance

• Use muteins with no substitution at positions 20/88/126 (as numbered in SEQ ID NO:1).
• Or use muteins that change function via different residues while maintaining IL-2 activity.

2. Process avoidance

• Avoid PBMC contact to generate a Treg-containing population for infusion.
• Use in vivo IL-2 mutein dosing rather than ex vivo PBMC reprogramming, unless the claim language is expanded by other claims not provided here.

3. Outcome avoidance

• Avoid producing a population that “comprises regulatory T cells” under the patent’s intended definition.
• In practice, this is harder than residue avoidance because most Treg expansion strategies create mixed populations with Tregs.

Combination avoidance

• Changing concomitant immunosuppressant choices likely does not avoid claims 1-6 if the core IL-2 mutein/Treg/adoptive transfer process is used.

Patent landscape implications for investors and competitors

Competitive relevance

This patent is strategically positioned to capture:

• IL-2 engineering programs that include substitutions at 20/88/126, and
• “cell therapy manufacturing” competitors that commercialize ex vivo Treg generation using IL-2 variants.

Likely licensing posture

Given the breadth of claim 1 on “at least one of positions 20/88/126,” the owner can present a relatively straightforward infringement theory against near-identical PBMC/Treg/adoptive-transfer protocols using related IL-2 muteins. That tends to support:

• cross-licensing pressure on IL-2 variant developers, and
• licensing pressure on cell therapy vendors if they adopt ex vivo IL-2 mutein contact.

Key Takeaways

• US 10,086,046 claims an ex vivo PBMC contact workflow that generates a Treg-containing cell population using hIL-2 muteins with substitutions at positions 20, 88, and/or 126 (SEQ ID NO:1 numbering), followed by adoptive transfer to treat type I diabetes, multiple sclerosis, or SLE.
• The enforceability hinge sits on two elements: (i) whether an accused IL-2 mutein includes substitutions at the claimed residue positions and (ii) whether the resulting cell product “comprises regulatory T cells.”
• Dependent claims 3, 5, and 6 focus on specific N88 and D20 and Q126 variants; claim 4 expands coverage through conservative additional substitutions.
• Claims 7-8 add broad immunosuppressant options and are unlikely to create strong novelty by themselves.
• For design-around, residue avoidance (not using substitutions at 20/88/126 as numbered in SEQ ID NO:1) is the cleanest path; process avoidance (not ex vivo PBMC-driven Treg generation for infusion) is the next best.

FAQs

1. Does claim 1 require a specific substitution identity at positions 20, 88, or 126?
   No. Claim 1 requires “an amino acid substitution” at at least one of those positions, with specific identities covered in dependent claims 3, 5, and 6.

2. Is the therapeutic target limited to the listed autoimmune diseases?
   Yes. Claim 1 limits the indication to type I diabetes, multiple sclerosis, or SLE.

3. Can the first and second organisms be different patients?
   Claim 2 allows the first and second organisms to be the same individual or individuals of the same species, leaving open homologous transfer within the same species framing.

4. Do claims 7-8 meaningfully constrain the IL-2 process?
   No. They add optional immunosuppressants from a broad list; they do not narrow the core IL-2 mutein/Treg/adoptive transfer requirements in the claim text provided.

5. What is the most direct design-around lever?
   Avoid hIL-2 muteins that include substitutions at positions 20, 88, or 126 as numbered in SEQ ID NO:1, and avoid the ex vivo PBMC-to-Treg population generation step for adoptive transfer.

References

[1] US Patent 10,086,046 (claim text provided in prompt).

Details for Patent 10,086,046

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	12-May-98		2037-02-22
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	2-Jan-03		2037-02-22
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	24-Aug-98		2037-02-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	31-Dec-02		2037-02-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	21-Feb-08		2037-02-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	24-Apr-13		2037-02-22
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	23-Sep-14		2037-02-22